DelveInsight’s, “Postpartum Depression Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the Postpartum Depression pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Postpartum Depression pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Postpartum Depression Pipeline. Dive into DelveInsight’s comprehensive report today! @ Postpartum Depression Pipeline Outlook

Key Takeaways from the Postpartum Depression Pipeline Report

• In March 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
• DelveInsight’s Postpartum Depression pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Diabetes treatment.
• The leading Postpartum Depression Companies such as GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
• Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO® and others.

Stay ahead with the most recent pipeline outlook for Postpartum Depression. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Postpartum Depression Treatment Drugs

Postpartum Depression Emerging Drugs Profile

• RE-104: Reunion Neuroscience

RE104 is a proprietary, potential best-in-class, serotonergic neuroplastogen. RE-104 is designed as a single-dose psychedelic that offers a fast onset and shorter treatment duration, as well as reproducible pharmacokinetics. It has potential across a variety of neuropsychiatric indications, including in PPD and AjD, where Reunion is focusing its initial clinical development efforts. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Postpartum Depression.

• GH001: GH Research

GH001 is an inhaled formulation of mebufotenin (5-MeO-DMT), a psychedelic compound that acts as a potent serotonin 5-HT1A and 5-HT2A receptor agonist. By rapidly modulating serotonergic signaling, GH001 is believed to induce profound and short-lasting psychoactive effects, which may help reset dysfunctional neural circuits implicated in mood disorders. It is being investigated for treatment-resistant depression (TRD), bipolar II disorder, and postpartum depression.

• BRII-297: Brii Bio

BRII-297 is a first-of-its-kind long-acting injectable (LAI) therapeutic candidate in development for the treatment of various anxiety and depressive disorders. Discovered internally, BRII-297 acts as a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator (PAM), a proven mechanism of action that is known to potentially restore “normal” levels GABAA receptor function for various depressive and anxiety central nervous system disorders. Currently, the drug is in Phase I stage of its clinical trial for the treatment of postpartum depression.

The Postpartum Depression Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Postpartum Depression with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postpartum Depression Treatment.
• Postpartum Depression Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Postpartum Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Postpartum Depression market

Explore groundbreaking therapies and clinical trials in the Postpartum Depression Pipeline. Access DelveInsight’s detailed report now! @ New Postpartum Depression Drugs

Postpartum Depression Companies

GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.

Postpartum Depression Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Postpartum Depression Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Postpartum Depression Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Postpartum Depression Market Drivers and Barriers

Scope of the Postpartum Depression Pipeline Report

• Coverage- Global
• Postpartum Depression Companies- GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.
• Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO® and others.
• Postpartum Depression Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Postpartum Depression Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Postpartum Depression Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Postpartum Depression Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Postpartum Depression: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Postpartum Depression – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Postpartum Depression Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Mid Stage Products (Phase II)
12. RE-104: Reunion Neuroscience
13. Early Stage Products (Phase I)
14. BRII-297: Brii Bio
15. Pre-clinical and Discovery Stage Products
16. Drug Name: Company Name
17. Inactive Products
18. Postpartum Depression Key Companies
19. Postpartum Depression Key Products
20. Postpartum Depression- Unmet Needs
21. Postpartum Depression- Market Drivers and Barriers
22. Postpartum Depression- Future Perspectives and Conclusion
23. Postpartum Depression Analyst Views
24. Postpartum Depression Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight